Millennium Management
SCNI

Millennium Management’s Scinai Immunotherapeutics SCNI Stock Holding History

Millennium Management’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,061
Closed -$5.48K – 6460
2024
Q1 		$5.48K Buy
+1,061
New +$5.47K ﹤0.01% 5997
2023
Q3 		– Sell
-1,158
Closed -$15.7K – 6506
2023
Q2 		$15.7K Sell
1,158
-3,202
-73% -$55.3K ﹤0.01% 5672
2023
Q1 		$94K Buy
+4,360
New +$108K ﹤0.01% 5445
2022
Q4 		– Sell
-123
Closed -$9K – 6994
2022
Q3 		$9K Buy
+123
New +$13.8K ﹤0.01% 6686
2022
Q2 		– Sell
-202
Closed -$34K – 7432
2022
Q1 		$34K Buy
+202
New +$29.3K ﹤0.01% 6513
2021
Q3 		– Sell
-116
Closed -$33K – 7194
2021
Q2 		$33K Buy
+116
New +$36.1K ﹤0.01% 6402

Other funds holding SCNI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Millennium Management's SCNI Position: Q2 2024 in Review

Millennium Management sold out of Scinai Immunotherapeutics (SCNI) in Q2 2024, closing a stake of 1,061 shares — an estimated $5.48K sold.

Millennium Management first reported a position in SCNI in Q2 2021 and held it in 6 quarters. The position peaked at $94K in Q1 2023. 9 funds tracked by Wall St. Rank hold SCNI as of Q2 2024.

  • Millennium Management reported no remaining Scinai Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Millennium Management sold 1,061 Scinai Immunotherapeutics shares in Q2 2024, an estimated $5.48K.
  • Millennium Management first reported a position in Scinai Immunotherapeutics in Q2 2021 and held it in 6 quarters.
  • Millennium Management's Scinai Immunotherapeutics position peaked at $94K in Q1 2023.
  • 9 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.